Investigational BPH drug shows promise in phase II trial

Patients with BPH who were treated with the investigational drug NX-1207 showed a total pooled mean improvement of 9.35 points in the primary outcome endpoint of AUA Symptom Score values at 3 months, researchers from Nymox Pharmaceutical Corp. reported. The results reached statistical significance when compared with placebo (p=.017).

Treated patients also showed an overall significant reduction in mean prostate volume of 11.7% (6.84 grams; p=.02). The double-blind, placebo-controlled study included 175 patients from 43 U.S. clinical trial sites.

Patients in the trial reported no significant sexual side effects or other serious side effects.